TherapeuticsMD, Inc. (TXMD) is a Healthcare stock trading at $2.06 (as of 2026-08-20), with a market capitalization of $23.79M and a trailing P/E of 47.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
TherapeuticsMD, Inc. is a women’s healthcare company in the United States that develops and sells prescription therapies including IMVEXXY for dyspareunia, BIJUVA for vasomotor symptoms, and ANNOVERA for contraception, along with related product candidates. It also manufactures and distributes branded and generic prenatal vitamins under multiple brands, selling to wholesale and retail pharmacy distributors.
TherapeuticsMD makes prescription women’s healthcare therapies, including IMVEXXY, BIJUVA, and ANNOVERA, and generates money by selling these treatments (with revenue tracked across products such as Anavera and Invexi).
TherapeuticsMD’s near-term profit potential depends on whether its prescription products convert new prescribers and then generate repeat usage (as reflected by KPIs like New Prescribers Added and Anavera Refill Rate), while costs remain covered at very low current revenue levels.
| Overall | $0.0B |
Business quality (Weak): Data quality is mixed. Latest-quarter revenue is effectively very small (overall net revenue candidate 0.02 USD_B), gross margin is not provided, and operating margin is reported as -99.9%, so profitability signals should be interpreted cautiously.
Valuation: At 98× earnings, TXMD trades 482% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $2.06 |
| Market Cap | $23.79M |
| P/E Ratio | 47.9 |
| Price / Book | 0.88 |
| Price / Sales | 7.67 |
| Revenue (TTM) | $3.02M |
| Net Margin | -18.8% |
| Revenue Growth (YoY) | 71.6% |
| EPS Growth (YoY) | -73.7% |
| Altman Z-Score | -34.08 (distress) |
| Stock P/E | 47.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | 120.8% |
| vs Industry | 182.2% |
| Top Institutional Holder | BlackRock Fund Advisors ($33.61M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Marlan D. Walker |
| Employees | 1 |
| Country | US |
| IPO Date | 2007-05-09 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.